Skip to content

Analysis of factors influencing the improvement of renal prognosis by uric acid-lowering drugs in patients with chronic kidney disease combined with hyperuricaemia and construction of a nomogram

Analysis of factors influencing the improvement of renal prognosis by uric acid-lowering drugs in patients with chronic kidney disease combined with hyperuricaemia and construction of a nomogram - Analysis of factors influencing the improvement of renal prognosis by uric acid-lowering drugs in patients with CKD combined with HUA and construction of a nomogram

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102755
Enrollment
Unknown
Registered
2025-05-20
Start date
2025-05-20
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease combined with hyperuricaemia

Interventions

Experimental group: patients diagnosed with chronic kidney disease combined with hyperuricemia and treated with uric acid-lowering therapy:None
Control group: patients with a diagnosis of chronic kidney disease combined with hyperuricemia and without uric acid-lowering therapy.:None

Sponsors

The First Affiliated Hospital of Chengdu Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age> 18 years old; 2. Meet the diagnostic criteria for CKD: CKD can be diagnosed if any one of the indicators in Table 1 appears for a duration of > 3 months; 3. Meet the diagnostic criteria for hyperuricemia: fasting blood uric acid (SUA) twice on the same day under normal purine diet: (1) Men and postmenopausal women> 420 µmol/L; (2) Non-menopausal women> 360µmol/L.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Malignant tumors; 3. Severe mental illness; 4. Patients with hemolytic diseases or acute renal failure; 5. Patients with poor compliance; 6. Patients lost to follow-up; 7. Follow-up time< 1 year; 8. Patients who have entered ESRD: eGFR<15ml/min.1.73m^2, patients who have undergone renal replacement therapy for hemodialysis or peritoneal dialysis.

Design outcomes

Primary

MeasureTime frame
uric acid;creatinine;Urine protein characterization;

Countries

China

Contacts

Public ContactXiao Xiang, Yu Haiyan

The First Affiliated Hospital of Chengdu Medical College

573923153@qq.com+86 181 0819 2604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026